First Light Biosciences Inc.

BEDFORD, MA · Biotech · Private

Platform for high-throughput screening and characterization of microorganisms using light-based detection and analysis

Claim this profile

Follows are private to you and power your alerts

Updated · first.tech

Sector
Biotech
Headquarters
BEDFORD, MA
Latest Form D
$3M, Aug 2018
Total capital
$6.7M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$6.7M
3 Form D · last Aug 2018
99 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
4 pending · first 2024
Rank in peer group#73 of 342

Capital timeline

2015201620172018FEDERAL ↑EQUITY ↓Cumulative $6.7M1st Form D$2.9M2nd Form D$811K3rd Form D$3M
2015201620172018FEDERAL ↑EQUITY ↓Cumulative $6.7M2nd Form D$811K3rd Form D$3M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$3M
  • Private capital raisedForm D · SEC · 2nd filing$811K
  • Private capital raisedForm D · SEC · 1st filing$2.9M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 342 peers

Line = median

Biotech · Platform

  • Granted patents#73 · top 21%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • David ShapiroDirectorNamed in SEC Form D filings
  • Donald StrausExecutive Officer, DirectorNamed in SEC Form D filings
  • Jeffrey ArnoldDirectorNamed in SEC Form D filings
  • Michael LyttonDirectorNamed in SEC Form D filings
  • Richard GanzDirectorNamed in SEC Form D filings
  • Salvatore SalamoneDirectorNamed in SEC Form D filings
Show all 9 people
  • Thierry BernardDirectorNamed in SEC Form D filings
  • Tripp PeakeDirectorNamed in SEC Form D filings
  • William MoffittDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 5
  • GrantedDetection Of TargetsUSPTOUS 12,031,985
  • PendingImaging Analyzer For Testing AnalytesUSPTOApplication 18520005
  • PendingDetection Of TargetsUSPTOApplication PCTUS2019028397
Show all 5 patent records
  • Detection Of TargetsJul 9, 2024 · US 12,031,985Granted
  • Imaging Analyzer For Testing AnalytesMar 21, 2024 · Application 18520005Pending
  • Detection Of TargetsApplication PCTUS2019028397Pending
  • Rapid And Sensitive Anthrax And Ast Tests On An Automated PlatformApplication 62711784Pending
  • Methods And Kits For Detecting Targets Such As MicrobesApplication 62660075Pending
  • Vima TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Lyndra Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Triveni BioSimilar federal contract value in Biotech · null in contracts
  • jCyte, Inc.Similar federal contract value in Biotech · null in contracts
  • Theravida, Inc.Similar federal contract value in Biotech · null in contracts
  • EpigenCare Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .